Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2015 / Sep / Pregnancy Risk Predictor
Omics Technology and innovation Research and Innovations

Pregnancy Risk Predictor

Will the risk of miscarriage or the promise of twins make it into at-home tests?

By Roisin McGuigan 09/28/2015 1 min read

Share

“Pregnant”, “Not Pregnant”: the two simple answers that you would expect all currently available pregnancy tests to provide. Picture this though… a home-based test that could predict likelihood of miscarriage, aneuploidy or even twins. Would putting that kind of information into the hands of consumers be a good thing? And how likely is it that such a test will be developed?

UK-based MAP Diagnostics believe in the value of such a test. In fact, their entire ethos is based on the empowerment of parents by providing rapid, reliable results, early in gestation to allow them to make informed decisions. To that end, it is using protein profiling to develop a test which provides early indications of pregnancy-related problems. Employing a technique more commonly applied to assisted reproduction, the company’s urine test will use mass spectrometry to identify protein biomarkers released by embryos, which will then be analyzed using an algorithm developed using a database of pregnant women, to spot patterns linked to various outcomes, such as Down’s syndrome (1). Using this approach, the company hopes to develop tests for a range of pregnancy-related conditions including gestational diabetes and ectopic pregnancy, and to predict a number of complications including intrauterine growth restriction and miscarriage. The approach will need a lot of further validation, but initial results for trisomy prediction look good – using an archive of 101 maternal urine samples, the test had 100 percent sensitivity and specificity at 12–14 weeks gestation. Although cfDNA screening is also being explored for this purpose, the creators of the urine test believe that, as a less invasive alternative which will reportedly be a fraction of the cost, protein profiling could offer a compelling alternative – and they plan for more tests to follow.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. RK Iles, et al., “Direct and rapid mass spectral fingerprinting of maternal urine for the detection of Down syndrome pregnancy”, Clin Proteomics, 12, eCollection (2015). PMID: 25878568.

About the Author(s)

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

More Articles by Roisin McGuigan

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Turning Tides
Omics
Turning Tides

January 9, 2024

3 min read

A new study shows evidence for sustained human-to-human transmission of mpox since 2016

“Pop” Goes the Sensor
Omics
“Pop” Goes the Sensor

January 19, 2022

1 min read

A new device could help scientists identify signs of arrhythmia, heart attack, and cardiac fibrosis

Improving Risk Stratification
Omics
Improving Risk Stratification

February 3, 2022

1 min read

Two genes have been identified that may be linked to prostate cancer outcomes

The Ultimate Vision for Rare Disease
Omics
The Ultimate Vision for Rare Disease

February 28, 2022

1 min read

Genomics and computational pathology can take rare disease diagnostics to the next level

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.